Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause AD, the risk of AD doubles about every five years beyond age 651. The World Health Organization estimates that about 50 million people living with dementia globally. In 2050, the number is expected to increase to 152 million2. In the U.S., a total of 122,019 recorded deaths were due to AD (2018), making it the 6th leading cause of death among adults in the country3. Hence, AD has a significant disease burden worldwide. Currently, the economic burden of AD is estimated to be $305 billion4. To date, there is no cure for dementia or AD. Read More >>
Ad
SNCA - Stem-Cell Based Therapy for Alzheimers Disease
- June, 14 2021 12:00 AM
- |
- Channelchek
- |
Market Wire News is a media platform, the information on this page was provided by Channelchek via Quote Media. Read our full disclaimer.
Link your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Contact the Author
News, Short Squeeze, Breakout and More Instantly...
Neuralstem Inc. Company Name:
SNCA Stock Symbol:
NASDAQ Market:
Ad
-
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
-
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
-
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc. - Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021 - New combined company, Palisades Bio, expected to begin trading on Nasdaq Capital...
Important Investor News Alert (OTC: AABB)
-
LAS VEGAS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the development of the new next generation AABB Wallet App is nearing completion. The AABB Wallet development team, led by the Koinfold Cr...